Positioning Arcellx for a Pivotal 2026: Anito-cel’s Differentiated Safety, Best-in-Class CAR T Launch Potential, and Undervalued Entry Point

Arcellx Inc, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst John Newman from Canaccord Genuity maintained a Buy rating on the stock and has a $130.00 price target.

John Newman has given his Buy rating due to a combination of factors that he believes position Arcellx for a strong pivotal period leading into 2026. He expects near-term acceptance of the BLA for anito-cel, likely with priority review, and views both accelerated and full approval scenarios as attractive given the therapy’s clear safety advantages and supportive randomized data from iMMagine-3. He also highlights the anticipated iMMagine-1 data update around mid-2026 as a catalyst for further clinical differentiation versus competing BCMA CAR T therapies, particularly if mature progression-free survival data are presented in a disciplined manner.

Newman further underscores the potential value of forthcoming mechanistic data explaining the absence of delayed neurotoxicity with anito-cel, which contrasts with the meaningful incidence seen with CARVYKTI and should reinforce confidence in anito-cel’s safety profile. On the commercial side, he anticipates an approval and launch in the second half of 2026 that could represent the strongest CAR T rollout to date, supported by broad center availability, high manufacturing reliability, and rapid turnaround times that address issues seen with earlier competitors. Combined with the recent pullback in the share price and what he sees as underappreciated upcoming milestones, he views the current valuation as an attractive entry point and maintains his $130 price target alongside a Buy recommendation.

Newman covers the Healthcare sector, focusing on stocks such as Arcellx Inc, Regeneron, and Atara Biotherapeutics. According to TipRanks, Newman has an average return of -0.6% and a 38.40% success rate on recommended stocks.

In another report released on January 9, Citi also maintained a Buy rating on the stock with a $110.00 price target.